Trial Profile
A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Ibrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 31 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 19 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Dec 2022.